2F-Viminol
{{Short description|Chemical compound}}
{{Drugbox
| drug_name = 2F-Viminol
| type =
| IUPAC_name = 2-[di(butan-2-yl)amino]-1-[1-[(2-fluorophenyl)methyl]pyrrol-2-yl]ethanol
| image = 2F-Viminol.svg
| width = 200
| alt =
| caption =
| tradename =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_UK = PSA
| legal_BR = F1
| legal_BR_comment = {{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2024-05-28 |title=RDC Nº 877 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 877 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-da-diretoria-colegiada-anvisa-n-877-de-28-de-maio-de-2024-562758149 |url-status=live |archive-url=https://web.archive.org/web/20240925040323/https://www.in.gov.br/en/web/dou/-/resolucao-da-diretoria-colegiada-anvisa-n-877-de-28-de-maio-de-2024-562758149 |archive-date=2024-09-25 |access-date=2024-09-25 |publisher=Diário Oficial da União |language=pt-BR |publication-date=2024-05-28}}
| legal_status = Illegal in Sweden and Latvia
| routes_of_administration =
| addiction_liability =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 63880-43-3
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K5W46P6ZPE
| ATC_prefix =
| ATC_suffix =
| PubChem = 57419227
| DrugBank =
| ChemSpiderID = 84400601
| C = 21
| H = 31
| F = 1
| N = 2
| O = 1
| melting_point =
| smiles = FC1=C(CN2C=CC=C2C(O)CN(C(CC)C)C(C)CC)C=CC=C1
| StdInChI = 1S/C21H31FN2O/c1-5-16(3)24(17(4)6-2)15-21(25)20-12-9-13-23(20)14-18-10-7-8-11-19(18)22/h7-13,16-17,21,25H,5-6,14-15H2,1-4H3
| StdInChIKey = FXQMNNHPOYWWKI-UHFFFAOYSA-N
}}
2F-Viminol is a pyrrole derived opioid analgesic drug, which was originally developed by a team at the drug company Zambon in the 1960s. It is around twice as potent as the parent compound viminol, though unlike viminol, 2F-viminol has never passed clinical trials or been approved for medical use. 2F-Viminol has been sold as a designer drug, first being identified in Sweden in 2019.{{cite web | title = Ordinance banning certain products that are harmful to health | url = https://ec.europa.eu/growth/tools-databases/tris/en/index.cfm/search/?trisaction=search.detail&year=2019&num=316&dLang=EN | work = Swedish Code of Statutes | date = 4 July 2019 | quote = This Ordinance enters into force on 6 August 2019 }} It is one of a number of structurally atypical opioid agonists to have appeared on the designer drug grey-market since broad controls over fentanyl analogues were introduced in China in 2015.{{cite journal | vauthors = Bao Y, Meng S, Shi J, Lu L | title = Control of fentanyl-related substances in China | journal = The Lancet. Psychiatry | volume = 6 | issue = 7 | pages = e15 | date = July 2019 | pmid = 31230685 | doi = 10.1016/S2215-0366(19)30218-4 | doi-access = free }} It was made illegal in Sweden in August 2019 and in Latvia in November 2019.{{cite web | title = SPKC nosaka aizliegumu vielām 2F-viminol, furanyl UF – 17 un to saturošiem izstrādājumiem | trans-title = SPKC bans 2F-viminol, furanyl UF-17 and products containing them | language = Latvian | url = https://www.spkc.gov.lv/lv/jaunums/spkc-nosaka-aizliegumu-vielam-2f-viminol-furanyl-uf-17-un-saturosiem-izstradajumiem-0 | work = Slimību profilakses un kontroles centrs (Center for Disease Prevention and Control) | date = 6 November 2019 }}